These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Physicochemical and biopharmaceutical characterization of amorphous solid dispersion of nobiletin, a citrus polymethoxylated flavone, with improved hepatoprotective effects. Onoue S; Nakamura T; Uchida A; Ogawa K; Yuminoki K; Hashimoto N; Hiza A; Tsukaguchi Y; Asakawa T; Kan T; Yamada S Eur J Pharm Sci; 2013 Jul; 49(4):453-60. PubMed ID: 23707470 [TBL] [Abstract][Full Text] [Related]
23. Amorphous multi-system of celecoxib improves its anti-inflammatory activity in vitro and oral absorption in rats. Choi JS; Ahn JB; Park JS Int J Pharm; 2019 Jan; 555():135-145. PubMed ID: 30458259 [TBL] [Abstract][Full Text] [Related]
24. Enabling direct compression tablet formulation of celecoxib by simultaneously eliminating punch sticking, improving manufacturability, and enhancing dissolution through co-processing with a mesoporous carrier. Paul S; Guo Y; Wang C; Dun J; Calvin Sun C Int J Pharm; 2023 Jun; 641():123041. PubMed ID: 37201765 [TBL] [Abstract][Full Text] [Related]
25. Exploration of supersaturable lacidipine ternary amorphous solid dispersion for enhanced dissolution and in vivo absorption. Guan J; Jin L; Liu Q; Xu H; Wu H; Zhang X; Mao S Eur J Pharm Sci; 2019 Nov; 139():105043. PubMed ID: 31415903 [TBL] [Abstract][Full Text] [Related]
26. Formulation, characterization, and in vivo evaluation of celecoxib-PVP solid dispersion nanoparticles using supercritical antisolvent process. Ha ES; Choo GH; Baek IH; Kim MS Molecules; 2014 Dec; 19(12):20325-39. PubMed ID: 25486246 [TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of meloxicam administered as regular and fast dissolving formulations to the rat: influence of gastrointestinal dysfunction on the relative bioavailability of two formulations. Aghazadeh-Habashi A; Jamali F Eur J Pharm Biopharm; 2008 Nov; 70(3):889-94. PubMed ID: 18715548 [TBL] [Abstract][Full Text] [Related]
28. Evaluation of Different Techniques for Size Determination of Drug Nanocrystals: A Case Study of Celecoxib Nanocrystalline Solid Dispersion. Kaur A; Parmar PK; Bansal AK Pharmaceutics; 2019 Oct; 11(10):. PubMed ID: 31591323 [TBL] [Abstract][Full Text] [Related]
29. Preparation, characterization, and evaluation of celecoxib eutectic mixtures with adipic acid/saccharin for improvement of wettability and dissolution rate. Hyun SM; Lee BJ; Abuzar SM; Lee S; Joo Y; Hong SH; Kang H; Kwon KA; Velaga S; Hwang SJ Int J Pharm; 2019 Jan; 554():61-71. PubMed ID: 30347274 [TBL] [Abstract][Full Text] [Related]
30. Assessment of celecoxib poly(lactic-co-glycolic) acid nanoformulation on drug pharmacodynamics and pharmacokinetics in rats. Harirforoosh S; West KO; Murrell DE; Denham JW; Panus PC; Hanley GA Eur Rev Med Pharmacol Sci; 2016 Nov; 20(22):4818-4829. PubMed ID: 27906418 [TBL] [Abstract][Full Text] [Related]
31. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim. Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464 [TBL] [Abstract][Full Text] [Related]
32. Hydrophilic polymer driven crystallization self-assembly: an inflammatory multi-drug combination nanosystem against Alzheimer's disease. Hu H; Wang J; Ren J; Li X; Zhang B; Lv Z; Dai F J Mater Chem B; 2021 Oct; 9(39):8272-8288. PubMed ID: 34505608 [TBL] [Abstract][Full Text] [Related]
33. Amorphous solid dispersion of cyclosporine A prepared with fine droplet drying process: Physicochemical and pharmacokinetic characterization. Suzuki H; Moritani T; Morinaga T; Seto Y; Sato H; Onoue S Int J Pharm; 2017 Mar; 519(1-2):213-219. PubMed ID: 28093327 [TBL] [Abstract][Full Text] [Related]
35. Anomalous dissolution behavior of celecoxib in PVP/Isomalt solid dispersions prepared using spray drier. Ghanavati R; Taheri A; Homayouni A Mater Sci Eng C Mater Biol Appl; 2017 Mar; 72():501-511. PubMed ID: 28024614 [TBL] [Abstract][Full Text] [Related]
36. Influence of polymer molecular weight on in vitro dissolution behavior and in vivo performance of celecoxib:PVP amorphous solid dispersions. Knopp MM; Nguyen JH; Becker C; Francke NM; Jørgensen EB; Holm P; Holm R; Mu H; Rades T; Langguth P Eur J Pharm Biopharm; 2016 Apr; 101():145-51. PubMed ID: 26899127 [TBL] [Abstract][Full Text] [Related]
37. Biopharmaceutical Study on Nobiletin-Loaded Amorphous Solid Dispersion with Improved Hypouricemic Effect. Nihei T; Ushiro E; Sato H; Onoue S Molecules; 2021 Jul; 26(15):. PubMed ID: 34361599 [TBL] [Abstract][Full Text] [Related]
38. Development of novel solid dispersion of tranilast using amphiphilic block copolymer for improved oral bioavailability. Onoue S; Kojo Y; Suzuki H; Yuminoki K; Kou K; Kawabata Y; Yamauchi Y; Hashimoto N; Yamada S Int J Pharm; 2013 Aug; 452(1-2):220-6. PubMed ID: 23694807 [TBL] [Abstract][Full Text] [Related]
39. Molecular Factors Governing the Liquid and Glassy States Recrystallization of Celecoxib in Binary Mixtures with Excipients of Different Molecular Weights. Grzybowska K; Chmiel K; Knapik-Kowalczuk J; Grzybowski A; Jurkiewicz K; Paluch M Mol Pharm; 2017 Apr; 14(4):1154-1168. PubMed ID: 28241116 [TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of celecoxib in the presence and absence of interferon-induced acute inflammation in the rat: application of a novel HPLC assay. Guirguis MS; Sattari S; Jamali F J Pharm Pharm Sci; 2001; 4(1):1-6. PubMed ID: 11302784 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]